Telix Pharmaceuticals

Telix Pharmaceuticals ROCE

The Return on Capital Employed (ROCE) of Telix Pharmaceuticals (TLX.AX) as of Nov 19, 2026 is 7.44 %. In the previous year, Return on Capital Employed (ROCE) was 15.47 % — a change of -51.89% (lower).

ROCE

7.44 %

YoY

-51.89%

Last updated:

In 2025, Telix Pharmaceuticals's return on capital employed (ROCE) was 7.44 %, a -51.89% increase from the 15.47 % ROCE in the previous year.

The Telix Pharmaceuticals ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-33.09 USD
Jan 1, 2019
-40.47 USD
Jan 1, 2020
-45.05 USD
Jan 1, 2021
-3,565.57 USD
Jan 1, 2022
-113.51 USD
Jan 1, 2023
11.98 USD
Jan 1, 2024
15.47 USD
Jan 1, 2025
7.44 USD
The Telix Pharmaceuticals ROCE history
YEARROCEYoY
7.44 %-51.89%
15.47 %+29.14%
11.98 %-110.55%
-113.51 %-96.82%
-3,565.57 %+7,814.19%
-45.05 %+11.34%
-40.47 %+22.30%
-33.09 %+164.57%
-12.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Telix Pharmaceuticals's Return on Capital Employed (ROCE)

Telix Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Telix Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Telix Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Telix Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Telix Pharmaceuticals stock

Return on Capital Employed (ROCE) of Telix Pharmaceuticals is 7.44 % in 2025.

Return on Capital Employed (ROCE) of Telix Pharmaceuticals changed from 15.47 % to 7.44 %, representing a -51.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals